Boston Scientific faces more questions over Watchman implant’s effectiveness, risks

Boston Scientific faces more FDA questions over Watchman heart implant's risks

Boston Scientific (NYSE:BSX) may have to confront some tough questions when it faces a panel of FDA experts reviewing its Watchman stroke-preventing heart implant.

In panel documents released ahead of this week’s meeting, the FDA asked its advisory committee to keep in mind that the Watchman permanent left atrial appendage closure device failed in a recent study to meet a primary goal for effectiveness and that previous trials have raised questions about the risks surrounding implantation surgery.

The Watchman implant, already available in 30 countries, is introduced via catheter and threaded into the heart to close off the left atrial appendage and capture any blood clots that may form there.

A December 11 meeting of the FDA’s Circulatory System Devices Panel will discuss whether the Watchman device is safe and effective enough to recommend for FDA approval. Although the FDA is not bound by the recommendations of its advisory panels, it often follows their lead.

The FDA asked panel members to consider Watchman data from a variety of analyses, including the early PROTECT AF study, the newer PREVAIL trial and the CAP patient registry. The federal watchdog agency highlighted that results from the PREVAIL study failed to support the primary effectiveness endpoint, the same benchmark that researchers met in the earlier PROTECT trial.

Take the survey: Will the FDA’s Circulatory Devices panel OK Boston Scientific’s Watchman heart implant?

In March, Natick, Mass.-based Boston Scientific unveiled results from the Prevail clinical trial of the Watchman device, saying it met 2 of 3 co-primary endpoints for safety and effectiveness compared with drug therapy. Watchman achieved its 2 safety endpoints, but researchers found no differences in rates of stroke, systemic embolism and cardiovascular or unexplained death at 18 months between patients who received the Watchman device and those who were treated only with warfarin, a blood thinner.

The Prevail trial was launched in order to address safety concerns raised by a previous Watchman trial, Boston Scientific noted. The Protect AF trial showed that treatment with the Watchman device reduced a patient’s risk of hemorrhagic stroke compared with warfarin, but also showed an increase in procedure-related adverse events.

Wall Street seemed unperturbed by focus on the missed endpoint and surgical risks, with a Wells Fargo analyst optimistic on the outcome of this week’s panel.

"The FDA stresses a number of times in the briefing documents that the panel members should consider the totality of the data, which we think is a positive sign," Wells Fargo medtech analyst Larry Biegelsen wrote in a note to investors. "The FDA documents were more mixed than we anticipated which leads us to believe that the panel will be contentious but we still expect a positive outcome and approval."

Boston Scientific acquired the Watchman device along with AtriTech in a deal valued at $375 million in 2011. In August the device won expanded CE Mark approval in the European Union for the catheter-based clot-capture system, to patients with atrial fibrillation who can’t be treated with warfarin or new oral anticoagulants.

Boston Scientific’s stock slipped a bit in afternoon trading, with shares down 1.3% to $11.70 apiece as of about 2:50 p.m.

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]

Trackbacks

Leave a Reply